Additional file : Appendices 1-10

Interventions for management of post-stroke depression: A Bayesian network meta-analysis of 23 randomized controlled trials

Linghui Deng^{1*}, Xuejun Sun^{2*}, Shi Qiu^{3*}, Yao Xiong¹, Yuxiao Li¹, Lu Wang¹, Qiang Wei³, Deren Wang^{1#}, Ming Liu^{1#}

* LHD, XJS and SQ contributed equally as the first authors of this manuscript.

1. Stroke Clinical Research Unit, Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan. China.

2. Second Department of Psychiatry, Kangning Hospital, Anshan, Liaoning, China

3. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

#Correspondence to:

[#]Dr Ming Liu (full professor), Stroke Clinical Research Unit, Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan. China. Email: wyplmh@hotmail.com

OR

[#]Dr Deren Wang, Stroke Clinical Research Unit, Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan. China; wdr0128@qq.com

Additional file 1: Appendices 1-10

Abbreviations

- Appendix 1: PRISMA network meta-analysis checklist
- **Appendix 2: Search algorithms**
- **Appendix 3: References for included trials**
- Appendix 4: Description of included studies, outcomes
- Appendix 5: Risk of bias assessments within studies
- Appendix 6: Network plot for each outcome
- Appendix 7: Assessment of inconsistency
- Appendix 8: Treatment ranking and SUCRA plot for each outcome

Appendix 9: Subgroup analysis

Appendix 10: Post hoc analysis

Abbreviations

PSD= post-stroke depression HAMD= Hamilton Depression Rating Scale(or HRSD); DSM= Diagnostic and Statistical Manual of Mental Disorders RCT= traditional Chinese medicine SSRI= selective serotonin reuptake inhibitor TCA= tricyclic antidepressant SNRI= serotonin-norepinephrine reuptake inhibitors NRI= norepinephrine reuptake inhibitor N+A= nimodipine plus antidepressants TCM= traditional Chinese medicine rTMS= Repetitive Transcranial Magnetic Stimulation P+A= psychotherapy plus antidepressants FEWP=Free and Easy Wanderer Plus (a kind of Chinese medicine; its original Chinese Name is Jia-Wei-Xiao-Yao-San) MMSE= Mini-mental State examination; NR=not reported SD= standard deviation ITT = intention-to-treat PP= per protocol BDI=Beck Depression Inventory CT=computed tomography MRI=magnetic resonance imaging SAH=subarachnoid hemorrhage TIA=transient ischemic attack TCD=total cumulative dose

Appendix 2: Search algorithms

Medlin	ne
#1	"randomized controlled trial" [Publication Type]
#2	"controlled clinical trial" [Publication Type]
#3	"randomized" [Title/Abstract]
#4	"randomly" [Title/Abstract]
#5	"trial" [Title]
#6	"Randomized Controlled Trial as Topic" [MeSH]
#7	(#1) OR (#2) OR (#3) OR (#4) OR (#5) OR (#6)
#8	"PSD" [Title/Abstract]
#9	"post-stroke depression" [Title/Abstract]
#10	"post-stroke depressive"[Title/Abstract]
#11	"depression after stroke"[Title/Abstract]
#12	"depression in stroke patients"[Title/Abstract]
#13	"depression after cerebral apoplexy"[Title/Abstract]
#14	"depression after cerebrovascular accident"[Title/Abstract]
#15	"depression after cerebrovascular disease"[Title/Abstract]
#16	(#8) OR (#9) OR (#10) OR (#11) OR (#12) OR (#13) OR (#14) OR (#15)
#17	"Therapeutics" [Mesh] OR "Antidepressive Agents" [Mesh]
#18	"Serotonin Uptake Inhibitors" [Mesh] OR "Fluoxetine" [Mesh] OR "Sertraline" [Mesh] OR "Paroxetine" [Mesh] OR
	"Citalopram" [Mesh] OR "Fluvoxamine" [Mesh] OR "Escitalopram" [Title/Abstract]
#19	"Antidepressive Agents, Tricyclic" [Mesh] OR "Nortriptyline" [Mesh] OR "Imipramine" [Mesh] OR "Clomipramine" [Mesh]
	OR "Amitriptyline" [Mesh]
#20	"serotonin norepinephrine reuptake inhibitor" [Title/Abstract] OR "SNRI" [Title/Abstract] OR "Venlafaxine" [Mesh] OR
	"Duloxetine" [Mesh] OR "NRI" [Title/Abstract] OR "reboxetine" [Title/Abstract]
#21	"Monoamine Oxidase Inhibitors" [Mesh] OR "Methylphenidate" [Mesh] OR "aniracetam" [Title/Abstract] OR
	"psychostimulant" [Title/Abstract]
#22	"Drugs, Chinese Herbal" [Mesh] OR "Acupuncture Therapy" [Mesh]

#23	"Psychotherapy" [Mesh] OR "Behavior Therapy" [Mesh]
#24	"Transcranial Magnetic Stimulation" [Mesh] OR "Electroconvulsive Therapy" [Mesh]
#25	"Mindfulness" [Mesh] OR "Music Therapy" [Mesh] OR "General Surgery" [Mesh] OR "Rehabilitation" [Mesh] OR "Social
	Support" [Mesh] OR "Education" [Mesh] OR "Family" [Mesh] OR "Nurses" [Mesh]
#26	(#17) OR (#18) OR (#19) OR (#20) OR (#21) OR (#22) OR (#23) OR (#24) OR (#25)
#27	(#7) AND (#16) AND (#26)
232	

Embas	se
#1	'randomized controlled trial'/exp: ti,ab,kw
#2	'randomized controlled trial (topic)'/exp: ti,ab,kw
#3	random *: ti,ab,kw
#4	#1 OR #2 OR #3
#5	'PSD'/exp: ti,ab,kw
#6	'post-stroke depression'/exp: ti,ab,kw: ti,ab,kw
#7	'post-stroke depressive'/exp: ti,ab,kw
#8	'depression after cerebral apoplexy'/exp: ti,ab,kw
#9	'depression after cerebrovascular accident'/exp: ti,ab,kw
#10	'depression after cerebrovascular disease'/exp: ti,ab,kw
#11	'depression in stroke patients'/exp: ti,ab,kw
#12	'depression after stroke' /exp: ti,ab,kw
#13	#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR
#14	'therapeutics' /exp: ti,ab,kw OR 'antidepressive Agents' /exp: ti,ab,kw
#15	'tricyclic' /exp: ti,ab,kw
#16	'serotonin uptake inhibitors'/exp: ti,ab,kw
#17	'serotonin norepinephrine reuptake inhibitor'/exp: ti,ab,kw
#18	'monoamine oxidase inhibitors' /exp: ti,ab,kw
#19	'fluoxetine'/exp: ti,ab,kw OR 'sertraline'/exp: ti,ab,kw OR 'paroxetine'/exp: ti,ab,kw OR 'citalopram'/exp:
	ti,ab,kw
#20	'Chinese Herbal' /exp: ti,ab,kw OR 'acupuncture' /exp: ti,ab,kw

#21	'psychotherapy' /exp: ti,ab,kw OR 'behavior therapy' /exp:ti,ab,kw OR 'transcranial magnetic stimulation' /exp:
	ti,ab,kw OR 'electroconvulsive therapy'/exp: ti,ab,kw
#22	'mindfulness'/exp: ti,ab,kw OR 'music therapy'/exp: ti,ab,kw OR 'surgery'/exp: ti,ab,kw OR 'rehabilitation'/exp:
	ti,ab,kw OR 'education'/exp: ti,ab,kw
#23	(#14) OR (#15) OR (#16) OR (#17) OR (#18) OR (#19) OR (#20) OR (#21) OR (#22)
#24	(#4) AND (#13) AND (#23)
318	

Cochr	ane Library Central
#1	PSD: ti, ab, kw OR post- stroke depression: ti, ab, kw in Trials (Word variations have been searched)
#2	depression after cerebrovascular disease: ti, ab, kw OR depression after cerebral apoplexy: ti, ab, kw in Trials (Word
	variations have been searched)
#3	depression after stroke: ti, ab, kw in Trials (Word variations have been searched)
#4	depression in stroke patients : ti, ab, kw in Trials (Word variations have been searched)
#5	(#1) OR (#2) OR (#3) OR (#4)
#6	therapeutics: ti, ab, kw OR antidepressive: ti, ab, kw OR serotonin reuptake inhibitor: ti, ab, kw OR tricyclic: ti, ab, kw OR
	monoamine oxidase inhibitor: ti, ab, kw in Trials (Word variations have been searched)
#7	fluoxetine: ti, ab, kw OR sertraline: ti, ab, kw OR paroxetine: ti, ab, kw OR citalopram: ti, ab, kw OR reboxetine: ti, ab, kw
	in Trials (Word variations have been searched)
#8	trazodone: ti, ab, kw OR nortriptyline: ti, ab, kw OR escitalopram: ti, ab, kw OR psychostimulant: ti, ab, kw in Trials (Word
	variations have been searched)
#9	Chinese herbal medicine: ti, ab, kw OR acupuncture: ti, ab, kw OR behavior therapy: ti, ab, kw OR psychotherapy: ti, ab, kw
	in Trials (Word variations have been searched)
#10	transcranial magnetic stimulation: ti, ab, kw OR surgery: ti, ab, kw OR electroconvulsive therapy: ti, ab, kw OR mindfulness:
	ti, ab, kw OR music therapy: ti, ab, kw in Trials (Word variations have been searched)
#11	nurse: ti, ab, kw OR care: ti, ab, kw OR support: ti, ab, kw OR family: ti, ab, kw OR education: ti, ab, kw in Trials (Word
	variations have been searched)
#12	(#6) OR (#7) OR (#8) OR (#9) OR (#10) OR (#11)
#13	(#5) AND (#12)
602	

Appendix 3: References for included trials

- 1. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1, 297-300 (1984).
- 2. Andersen G, Vestergaard K, Lauritzen L, General F. Original contributions effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25(6):1099-1104.
- 3. Gonzalez-torrecillas JL, Mendlewicz J, Lob A. Effects of early treatment of post-stroke depression on neuropsychological rehabilitation. Int Psychogeriatr. 7, 547-560 (1995)
- 4. Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after post-stroke depression: A double-blind treatment trial. Stroke. 31, 1482–1486 (2000).
- 5. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke. Am J Psychiatry. 157, 351–359 (2000).
- 6. Taragano FE, Allegri R, Vicario A, Bagnatti P, Lyketsos CG. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'. Int J Geriatr Psychiatry. **16**, 254–260 (2001).
- Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression: A three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neuro. 250, 347–351 (2003).
- 8. Kimura M, Tateno A, Robert G, Robinson M. Treatment of post-stroke generalized anxiety disorder comorbid with post-stroke depression merged analysis of nortriptyline trials. Am J Geriatr Psychiatry. 11, 320–327 (2003)
- 9. Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology. 173, 73–78 (2004).
- 10. Rampello L, Alvano A, Chiechio S. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression: A random, placebo-controlled study. Arch Gerontol Geriatr. 40, 275–285 (2004).
- 11. Huang L. Comparison of therapeutic effects and side effects between fluoxetine hydrochloride and clomipramine in patients with vascular depression. Chin J Clin Rehabil. 9, 226–228 (2005).
- 12. Ye LX, Wang YD, Wang H, Liang DS. Effect of Paxil and berhomine on post-stroke anxiety-depression and neurological recovery. Chin J Clin Rehabil. 10, 153-155 (2006).
- 13. Li LT, Wang SH, Ge HY, Chen J, Yue SW, Yu M. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. J Altern Complement Med. 14, 841–846 (2008).
- 14. Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum. Psychopharmacol Clin Exp. 24, 331–336 (2009).
- 15. Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T. Duloxetine versus citalopram and sertraline in the treatment of post-stroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci. 24,349–353 (2012).
- 16. Jorge RE, Robinson RG, Tateno A, Narushima K, Acion L, Moser D, et al. Repetitive transcranial magnetic stimulation as treatment of post-stroke depression: A preliminary study. 55, 398–405 (2004).
- 17. Jorge RE. Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry. 65, 268-276 (2008).
- 18. Tenev V, Robinson RG, Jorge RE. Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression. Am J Geriatr Psychiatry. 17, 682–687 (2010).
- Narushima K, McCormick L, Yamada T, Thatcher R, Robinson RG. Subgenual cingulate theta activity predicts treatment response of repetitive transcranial magnetic stimulation in participants with vascular depression. J Neuropsychiatry Clin Nerosci. 22, 75-84 (2010).
- 20. Seo YG, Chang MC. The Effects of 10-Hz Repetitive Transcranial Magnetic Stimulation on Depression in Chronic Stroke Patients. [published online ahead of print October 18, 2016]. Brain Stimul. http://www.brainstimjrnl.com/article/S1935-861X(16)30270-4/abstract. Accessed September 9, 2016.
- 21. Feng SZ, Zhang MY, Dai AH. Impacts of rehabilitative therapy on post-stroke depression and the ability of daily life. Chin J Clin Rehabil. 9, 154-155 (2005).
- 22. Williams LS, Kroenke K, Bakas T, Plue LD, Brizendine E, Hendrie H. Care Management of Poststroke Depression: A Randomized, Controlled Trial. Stroke. 38, 998–1003 (2007).

- 23. Mitchell PH. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke. **40**, 3073–3078 (2009).
- 24. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early post-stroke depression: a double-blind placebo-controlled study. Stroke. **31**, 1829–32 (2000).
- 25. Murray V, Von ArbinM, Bartfai A, Berggren A, Landtblom A, Lundmark J, Martensson B. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry. **66**, 708-716 (2005)

Appendix 4: Description of included studies, outcomes

Table1. Study characteristic

			Exclusion criteria			
		diseases limiting verbal	psychiatric illness or			profile of prior antidepressant
study	Inclusion criteria	comprehension ^a	substance abuse	CNS diseases	others	therapy
						only included patients never
	thromboembolic stroke or intracerebral hemorrhage; moderate or	severe comprehension			medical contraindication	being treated with
Lipsey 1984	severe depression; with informed consent	deficit	-	-	to nortriptyline	antidepressants
				SAH; Binswanger's		
			history of psychiatric	disease; previous		
		decreased	illness (except	degenerative or		
		consciousness; aphasia;	depression more than 1	expansive neurological		exclude current antidepressant
Andersen 1994	acute stroke with depression	dementia	year earlier)	diseases ^b	-	treatment
			alcoholism, drug abuse,			
			any pathological			
		aphasia >2b/3 according	condition capable of			exclude antidepressant
	unilateral lesion documented by CT scan and capable of	to the Goodglass	resembling a depressive			treatment in the 6 months
Gonzalez 1995	compliance were included. with informed consent.	criteria	condition	-	-	before stroke

						patients who taking
				head injury, prior or		antidepressants were required
	acute stroke within 6 months of the onset of the study and age 18-	severe comprehension		other brain disease		to stop the therapy before the
Robinson 2000	85	deficit	-	except prior stroke	significant medical illness	study (N=3).
		decreased				
	acute thromboembolic or intracerebral hemorrhagic infarction	consciousness; aphasia;				
Kimura 2000	who were identified as depressed	dementia	-	-	-	-
	With vascular depression , and met DSM-IV criteria for major					
Taragano 2001	depressive episode	MMSE<24	-	-	too ill medically	-
	thromboembolic stroke or intracerebral hemorrhage were verified	more than mild		previous degenerative		
	by CT. moderate or severe depression, as measured by a	communication deficit;		or expansive		
Fruehwald 2003	HAMD>15	MMSE<20	-	neurological diseases	-	-
		decreased				
	acute thromboembolic or intracerebral hemorrhagic infarction,	consciousness; aphasia;				
Kimura 2003	and identified as depressed	dementia	-	-	-	-
		decreased	history of psychiatric	previous degenerative		
	presence of a recent (<12 months) single ischemic or	consciousness; severe	illness (except	or expansive	respiratory complications;	
	hemorrhagic stroke, which was documented by CT or MRI;	aphasia, severe	depression for more	neurological diseases,	serious heart diseases;	lack of antidepressant
	presence of major or minor depression, according to DSM IV	cognitive	than 1 year); chronic	SAH, Binswanger's	under anticoagulant	treatment within 30 days prior
Rampello 2003	criteria, with HDRS>20, BDI> 15	deficit(MMSE <22)	alcoholism,	disease	treatment	to this study

	presence of a recent (<12 months) single ischemic or hemorrhagic		history of psychiatric	previous degenerative		
	stroke, (documented by CT or MRI); presence of major or minor		illness (other than	or expansive neurologic		lack of antidepressant
	depression, according to DSM IV criteria, with HDRS>20 and	severe aphasia, severe	depression); chronic	disease, SAH,		treatment within 2 weeks prior
Rampello 2004	BDI>15; with informed consent.	cognitive deficit	alcoholism.	Binswanger's disease	-	to this study
		decreased			severe impairment in cardiac	
		consciousness;		trauma, tumor,	function, hepatic function or	
		dementia; severe mental		inflammation or	renal function;	
Huang 2005	with diagnosis of vascular depression; less than 70 years old	disorders	history of depression	demyelination in brain	history of drug allergy	-
		decreased				
		consciousness;				
	post-stroke anxiety and depression, with HAMD-24>21 and	understanding				
Ye 2006	HAMA-14>14	problems;	-	-	without stable life signs	-
		r ·····				
			a history of psychiatric			
	presence of a recent (<6 weeks) single ischemic or hemorrhagic		illness other than			lack of before the enrolment
	stroke, documented by CT or MRI; presence of major or minor	severe aphasia;	depression; chronic			within 2 weeks prior to this
Li 2008	depression, with a HAMD>20	MMSE<23	alcoholism	epilepsy	abnormal thyroid function	study
				stroke history;		
		severe cognitive	history of psychiatric	degenerative or		
	first-ever stroke diagnosis within the last 12 months and diagnosis	impairment	disorders, within 5	expansive neurological	atherosclerotic disease,	
Cravello 2009	of post-stroke major depressive-like episode.	(MMSE<12)	years before the stroke	diseases	major medical illnesses	-
			history of a major	stroke history;	atherosclerotic disease or a	
	diagnosis of the first-ever stroke within the last 12 months, based	dementia; Severe	psychiatric disorder	degenerative or	history of angioplasty or	
	on clinical history, physical examination, and findings of brain	cognitive	within 5 years before	expansive neurological	bypass surgery; major	
Dimitrios 2012	MRI; Diagnosis of PSD, according to DSM-IV.	impairment(MMSE<24)	the stroke.	diseases	medical illness	-

1						
			actively suicidal; active			
		aphasia or with	psychosis; bipolar	degenerative		
	cortical or subcortical ischemic lesions of the right hemisphere	language	course; alcohol or drug	neurological diseases ;	severe systemic disease;	
	and subcortical lesions or posterior cortical lesions of the left	comprehension deficits;	abuse during the past 12	major head trauma,	ongoing neoplasia;	patients were unresponsive to
Jorge 2004	hemisphere.	MMSE<23	months	epilepsy	contraindications for rTMS ^c	antidepressants
	major depressive disorder (as diagnosed by DSM-IV criteria) at		suicidal; active			Patients were unresponsive to
	age 50 years or older, a history of subcortical stroke, and/or at		psychosis; comorbid		severe heart or respiratory	antidepressants; patients who
	least 3 of the following cardiovascular risk factors: arterial		alcohol or other drug	degenerative	failure; renal or hepatic	taking antidepressants were
	hypertension, diabetes mellitus, obesity, hyperlipidemia, and		abuse within 2 years	neurological diseases;	failure; ongoing neoplasia;	required to stop the therapy
Jorge 2008	smoking	dementia	before the study	head trauma, epilepsy	contraindications for rTMS	before initiation of rTMS
						patients were unresponsive to
	age between 50 and 90 years old; major depressive disorder (as					antidepressants;
	diagnosed by the DSM-IV-TR) with HAMD>14; a history of		suicidal thought, plan,	degenerative		patients who taking
	stroke or at least three of the following cardiovascular risk factors:		or delusion; substance	neurological diseases;	life-threatening physical	antidepressants were required
	arterial hypertension, diabetes mellitus, obesity, hyperlipidemia,	severe aphasia;	abuse within the prior 2	prior seizure or	illness;	to stop the therapy before
Narushima 2010	and smoking	dementia	years;	traumatic brain injury	contraindications for rTMS	initiation of rTMS
	with onset of major depression at age 50 or older, with a history of					patients who taking
	subcortical stroke or at least 3 of the following cardiovascular risk					antidepressants were required
	factors: arterial hypertension, diabetes mellitus, obesity,				severe coexistent medical	to stop the therapy before
Tenev 2010	hyperlipidemia, and smoking	-	psychotic depression	-	illness	initiation of rTMS
						patients with medication
					serious medical	history of antidepressants
	history of stroke ≥ 6 months; aged between 21 and 80 years; the	aphasia; severe	depression before stroke		complication;	before stroke onset were
Seo 2016	presence of depression (BDI>12 and HAMD-17>6)	cognitive dysfunction	onset;	_	contraindications for rTMS	excluded
500 2010	presence of depression (DDF 12 and TrAviD-17-0)	cognitive dystanction	unset,			CACINGCU
		decreased				
		consciousness; aphasia;				
		cognitive disorder;				
Feng 2004	stroke patients with depression	mental disorder	-	previous stroke history	serious condition	-

						patients were not excluded for
			active psychosis;			prior antidepressant treatment
	could speak and understand English, had a telephone, and who	aphasia; dementia;	suicidality; substance		women pregnant at the	either before or at the time of
Williams 2007	had a life expectancy of at least 6 months	MMSE<23	abuse	hemorrhagic stroke	time of stroke	the stroke
	within 4 months of an ischemic stroke, verified by CT or MRI,					patients were not excluded for
	who screened positive for depressive symptoms, and whose		active psychosis; drug			prior or current antidepressant
Mitchell 2009	diagnosis of clinical depression was verified by DSM IV criteria	-	abuse	-	-	treatment

^aDiseases limiting verbal comprehension including decreased consciousness, aphasia, dementia, and cognitive disorder.

^bDegenerative neurological diseases including Parkinson disease and Alzheimer disease; expansive neurological diseases including multiple sclerosis, tumor, hydrocephalus, and amyotrophic lateral sclerosis.

^cContraindications for rTMS including epileptic seizure, the presence of metal in the skull, pacemaker placement, frontal cortex lesion or hemorrhagic stroke (to avoid rTMS induced seizure).

HAMD= Hamilton Depression Rating Scale(or HRSD);

DSM= Diagnostic and Statistical Manual of Mental Disorders

CT=computed tomography

MRI=magnetic resonance imaging

SAH=subarachnoid hemorrhage

TIA=transient ischemic attack

TCD=total cumulative dose

MMSE= Mini-mental State examination;

BDI=Beck Depression Inventory

Table 2. Treatment characteristic

study	duration	intervention/control group (N and maximum daily dose)				
Lipsey 1984	6 weeks	Nortriptyline (N=14;100mg/d)	Placebo (N=20)	-		
Andersen 1994	6 weeks	Citalopram (N=33;20mg/d)	Placebo (N=33)	-		
Gonzalez 1995	alez 1995 6 weeks Fluoxetine (N=26;20mg/d)		Nortriptyline (N=11;75mg/d)	Placebo (N=11;100mg/d)		
Robinson 2000	12 weeks	Fluoxetine (N=23;40mg/d)	Nortriptyline (N=16,100mg/d	Placebo (N=17)		
Kimura 2000	6 or 12 weeks	Nortrityline (N=21;100mg/d)	Placebo (N=26)	-		
Taragano 2001	60 days	Nimodipine + antidepressants (N=40,90mg/d)	SSRI (N=44)	-		
Fruehwald 2003	12 weeks	Fluoxetine (N=28; 20mg/d);	Placebo (N=26)	-		
Kimura 2003	6 or 12 weeks	Nortrityline (N=13;100mg/d)	Placebo (N=14)	-		

Rampello 2003	16 weeks	Citalopram (N=37;20mg/d)	Reboxetine (N=37;4mg/d)	-
Rampello 2004	16 weeks	Reboxetine (N=16;4mg/d);	Placebo (N=15)	-
Huang 2005	12 weeks	Fluoxetine (N=30;20mg/d)	Clomipramine (N=30;750mg/d)	-
Ye 2006	12 weeks	Paroxetine (N=29;20mg/d)	Imipramine (N=27;150mg/d)	Control (n=27)
Li 2008	8 weeks	FEWP (N=60;36g/d)	Fluoxetine (N=60;40mg/d)	Placebo (N=30;36g/d)
Cravello 2009	8 weeks	Fluoxetine (N=25;40mg/d)	Venlafaxine (N=25;150mg/d)	-
Dimitrios 2012	3 months	Duloxetine (N=20;120mg/d)	Citalopram (N=20;40mg/d)	Sertraline (N=20;200mg/d)
Jorge 2004	2 weeks	Active rTMS (N=10;TCD=12K ^a)	Sham rTMS (N=10)	-
Jorge 2008 ^c	3 weeks	Active rTMS (N=15;TCD=12K) (N=33;TCD=18K ^b)	Sham rTMS (N=15) (N=29)	-
Narushima 2010	2 weeks	Active rTMS (N=43;TCD=12k/18k)	Sham rTMS (N=22)	-
Tenev 2010	Tenev 2010 2 weeks Active rTMS (N=33;TCD=18k)		Sham rTMS (N=29)	-
Seo 2016	2 weeks	Active rTMS (N=12;TCD=12K)	Sham rTMS (N=12)	-

Feng 2004	6 months	Psychotherapy (N=30)	Control (N=30)	-
Williams 2007	12 weeks	P+A ^d (N=89)	Control (N=93)	-
Mitchell 2009	8 weeks	P+A ^e (N=48)	SSRI (N=53)	-

^a12K=12 000 magnetic pulses.

^b18K=18 000 magnetic pulses.

^cThe patients were randomized divided into two intervention group: 12K-group and 18K-group

^dMost patients used SSRI, while some patients used an alternate antidepressant, based on his or her own assessment

^ePatients used paroxetine, or sertraline (for subjects who had a history of side effects or lack of response to paroxetine), or changed to venlafaxine (for subjects with <50% drop in PHQ-9 score at 6 weeks).

P+A= Psychotherapy plus antidepressants therapy

TCM= traditional Chinese medicine

SSRI=selective serotonin reuptake inhibitor

rTMS= Repetitive Transcranial Magnetic Stimulation

Table 3. Results of individual studies

3-1 reduction of HAMD score between pre- and post- treatment of all treatments

		SSRI			ТСА			SNRI			NRI			N+A			ТСМ			CONTR	OL		rTMS			P+A		Psy	chother	apy
	n	mean	sd	n	mean	sd	n	mean	sd	n	mean	sd	n	mean	sd	n	mean	sd	n	mean	sd	n	mean	sd	n	mean	sd	n	mean	sd
Lipsey 1984				11	11.14	0.69													15	6.39	1.03									
Andersen 1994	33	8	6																33	4.8	4.6									

Gonzalez 1995	25	16.37	7.9	10	14.68	0.35													10	2.11	0.36						
Robinson 2000	14	1.9	6.64	13	13.5	7.47													13	5.3	5.6						
Kimura 2000				18	12.05	5.53													26	6.84	6.76						
Taragano 2001	44	13.08	4.21										40	15.6	5.67												
Fruehwald 2002	26	23.3	12																24	19.1	15.1						
Kimura 2003				13	10.2	8.2													14	2.8	7.4						
Rampello 2003- (retarded) ^a	14	2.58	3.89							15	13.58	2.49															
Rampello 2003- (anxious) ^a	20	13.95	2.02							19	1.89	3.62															
Rampello 2004										16	14.8	1.91							15	1.27	2.08						
Huang 2005	30	13.5	3.8	30	12.19	3.64																					
Ye 2006	29	21.16	6.095	27	19.18	7.97													27	7.8	4.591						
Li 2008	58?	10.8	2.81													60	10.6	3.36	28	5.6	3.5						
Cravello 2009	25	9.07	4.17				25	7.33	4.23																		
Dimitrios 2012 ^b	40	20.1	6.24				20	21.1	6.87																		
Jorge 2004																			10	2.7	1.51	10	7.3	1.51			

Jorge																						
2008-											15	2.71	1.03	15	6.45	1.03						
(12K) ^c																						
Jorge																						
2008-											29	3.08	6.09	33	7.8	4.7						
(18K) ^c																						
Narushima											11	3.8	1 77	32	5 27	2.50						
2010											11	5.6	1.77	52	5.27	2.59						
Seo 2016											12	-0.3 ^d	0.79	12	3.2	1.13						
Feng 2004											30	-1.2 ^d	7.02							30	3.4	4.5
Williams											93	5.4	0				80	7.4	7.2			
2006											73	5.4	8				89	7.4	1.2			
Mitchell 2009	53	3.6	5.6														45	9.8	4.9			

^aThe author divided PSD patients into "retarded" and "anxious" groups, and in each group the patients were randomized into citalopram and reboxetine subgroups.

^bData of SSRI group were pooled from two group: citalopram group (n=20; mean HAMD=21; sd=5.96) sertraline group (n=20; mean HAMD=19.6; sd=6.6)

^cThe anthor divided PSD patients into 2 group according to the total cumulative dose(TCD) the active groups accepted.

^dMinus represents increase of HAMD score which means the HAMD scores were increased after treatnents.

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

SNRI= serotonin-norepinephrine reuptake inhibitors

NRI= norepinephrine reuptake inhibitor

N+A= nimodipine plus antidepressants

TCM= traditional Chinese medicine

rTMS= Repetitive Transcranial Magnetic Stimulation

P+A= psychotherapy plus antidepressants

	SS	RI	TC	CA	N	+A	TC	CM	CON	ſROL	rTl	MS	P+	A
	Response	n	response	n	response	n								
Robinson 2000	2	23	10	16					4	17				
Kimura 2000			16	21					8	26				
Taragano 2001	25	44			27	40								
Fruehwald 2002	18	26							18	24				
Kimura 2003			9	13					3	14				
Huang 2005	25	30	25	30										
Ye 2006	20	29	18	27					7	27				
Li 2008	38	58					36	60	6	28				
Jorge 2004									0	10	3	20		
Jorge 2008-(12K) ^a									1	15	5	15		
Jorge 2008-(18K) ^a									2	29	13	33		
Narushima 2010									1	11	14	32		
Tenev 2010									2	29	13	33		
Williams 2006									28	93			45	89

^aThe anthor divided PSD patients into 2 group according to the total cumulative dose(TCD) the active groups accepted.

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

N+A= nimodipine plus antidepressants

TCM= traditional Chinese medicine

rTMS= Repetitive Transcranial Magnetic Stimulation

P+A= psychotherapy plus antidepressants

3-3 remission of all treatments

	SS	RI	TC	ĊA	N-	⊦A	CON	FROL	rTl	MS	P-	A
	remission	n	remission	n	remission	n	remission	n	remission	n	remisison	n
Andersen 1994	16	27					9	32				
Taragano 2001	11	44			18	40						
Ye 2006	7	29	6	27			2	27				
Jorge 2004							0	10	1	10		
Jorge 2008- (12K) ^a							1	15	2	15		
Jorge 2008- (18K) ^a							1	29	9	33		
Narushima 2010							0	11	11	32		
Williams 2006							21	93			35	89
Mitchell 2009	10	53									21	45

^aThe anthor divided PSD patients into 2 group according to the total cumulative dose(TCD) the active groups accepted.

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

N+A= nimodipine plus antidepressants

rTMS= Repetitive Transcranial Magnetic Stimulation

P+A= psychotherapy plus antidepressants

						SS	SRI								SI	NRI							ТСА						NRI			ТСМ	[С	ONTR	.OL
	:	sertrali	ne	:	sertralii	ne	t	fluoxeti	ne]	paroxet	ine	ć	luloxet	ine	v	enlafax	tine	ir	nipram	ine	clo	omiprar	nine	nc	ortripty	line	re	eboxeti	one		ee and l	-		contro	01
	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd	n	me an	sd
Lipsey 1984																									1	11. 14	0. 69							1 5	6.3 9	1.0 3
Anders en 1994	3 3	8	6																															3 3	4.8	4.6
Gonzal ez 1995							2 5	16. 37	7. 9																1 0	14. 68	0. 35							1 0	2.1 1	0.3 6
Robins on 2000							1 4	1.9	6. 64																1 3	13. 5	7. 47							1 3	5.3	5.6
Kimura 2000																									1 8	12. 05	5. 53							2 6	6.8 4	6.7 6

3-4 reduction of HAMD score between pre- and post- treatment of antidepressants

Fruehw ald 2002					2 6	23. 3	12																						2 4	19. 1	15. 1
Kimura 2003																				1 3	10. 2	8. 2							1 4	2.8	7.4
Rampe llo 2003- (anxiou s) ^a	2 0	13. 95	2. 02																				1 9	1.8 9	3. 62						
Rampe llo 2003- (retard ed) ^a	1	2.5 8	3. 89																				1 5	13. 58	2. 49						
Rampe llo 2004																							1 6	14. 8	1. 91				1 5	1.2 7	2.0 8
Huang 2005					3 0	13. 5	3. 8										3 0	12. 19	3. 64												
Ye 2006								2 9	21. 16	6.0 95				2 7	19. 18	7. 97													2 7	7.8	4.5 91
Li 2008					5 8	10. 8	2. 81																			6 0	10. 6	3. 36	2 8	5.6	3.5

Cravell							2	9.0	4.					2	7.3	4.2									
o 2009							5	7	17					5	3	32									
Dimitri	2	20.	5.	2	19.	6.					2	21.	6.												
os 2012	0	6	96	0	6	62					0	1	87												

^aThe author divided PSD patients into "retarded" and "anxious" groups, and in each group the patients were randomized into citalopram and reboxetine subgroups.

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

SNRI= serotonin-norepinephrine reuptake inhibitors

NRI= norepinephrine reuptake inhibitor

TCM= traditional Chinese medicine

3-5 response of all antidepressants

		SS	SRI					TCA			TCM		CONTROI	
	fluoxetine		paroxetine	1	imipramine	e	clomiprami	ne	nortriptyline		Free and Ea Wanderer P	-	control	
	Response	n	Response	n	Response	n	response	n	response	n	response	n	Response	n
Robinson 2000	2	23							10	16			4	17
Kimura 2000									16	21			8	26
Fruehwald 2002	18	26											18	24
Kimura 2003									9	13			3	14
Huang 2005	25	30					25	30						
Ye 2006			20	29	18	27							7	27

Li 2008 38 5	58			36 6	60 6	28
--------------	----	--	--	------	------	----

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

TCM= traditional Chinese medicine

3-6 remission of antidepressants

		SSRI			т	CA	CONTR	.OL
	citalopra	m	paroxet	ine	imipr	amine	contro	ol
	remission	n	remission	n	remission	n	remission	n
Andersen 1994	16	27					9	32
Ye 2006			7	29	6	27	2	27

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

Table 4. Overview of treatments in the included trials and in the network meta-analysis

intervention groups	Trial group/arms				
TCA, tricyclic antidepressants	7 arms in total				
	5 nortriptyline				
	1 imipramine				
	1 clomipramine				
SSRI, selective serotonin reuptake inhibitors	14 separate groups in trials, after pooling of 2 arms in a study				
	with 2 SSRI, 13 arms in analyses				
	4 citalopram (1 pooled with sertraline, 2 from 1 trial ^a)				
	1 sertraline (pooled with citalopram)				
	6 fluoxetine				

1 paroxetine
2 mixed use of SSRIs
2 arms in total
1 duloxetine
1 venlafaxine
3 arms in total
3 reboxetine (2 from 1 trial ^a)
1 arms in total
1 Free and Easy Wanderer Plus
6 arms in total (2 from 1 trial ^b)
3 TCD=12k
2 TCD=18k
1 TCD=12k or 18k
1 arm in total
1 arms in total
1 nimodipine plus antidepressants
2 arms in total
2 psychotherapy plus antidepressants

^aIn trial of "Rampello 2003", the author divided PSD patients into "retarded" and "anxious" groups, and in each group the patients were randomized into citalopram and reboxetine subgroups.

^bIn trial of "Jorge 2008", the anthor divided PSD patients into 2 group according to the total cumulative dose(TCD) the active groups accepted.

Table 5. Adverse events of individual studies

study	Adverse events (Showed as events n(%))					
Study	Group 1	Group 2	Group 3			

Lipsey 1984	nortriptyline: dizziness 1; delirious 3; sedated 1; syncopal 1	placebo: mania 1; refused interview or unfollowed 3; death 2(heart-failure 1; ICH 1); dizziness 1	
Andersen 1994	citalopram: new stroke 3(thromboembolic 1; ICH 1; TIA 1); epilepsy 2; rash 1; death 2(both not because of heart-failure)	placebo: death 2(heart-failure) ; heart-failure 1; acute myocardial infarction 1; new stroke 2(thromboembolic 1;TIA 1); rash 1	
Gonzalez 1995	fluoxetine:1 drop out because of side effects;	nortriptyline:1 drop out because of side effects	control: unfollowed
Robinson 2000	fluoxetine: gastrointestinal symptoms 3; refused treatment 6;	nortriptyline: medical deterioration 2; refused treatment 1	placebo: death 1(pulmonary embolus 1); medical deterioration 1; refused treatment 2
Kimura 2000		NR	
Taragano 2001	nimodipine: hypotention 7; nausea 2; headache 2; dizziness 4;retarded ejaculation 1; epigastric pains 3; bradycardia 1; vertigo 1; insomnia 1; diarrhea 1; any one 21	control: hypotention 1; nausea 5; headache 4; dizziness 1; dry mouth 3; retarded ejaculation 2; bradycardia 1; anorexia 2; phobia 1; bronchitis 1; any one 18	
Fruehwald 2003	fluoxetine: death 1; pulmonary artery embolism 1	placebo: medical deterioration 1(suicidal 1); dermatological disease 1	
Kimura 2003		NR	
Rampello 2003	citalopram: nausea (3%), vomiting (2%), asthenia and fatigability (4%), opening insomnia (18%), weight increase (12%), and reduction of sexual activity (7%).	reboxetine: dry mouth (19%), constipation (16%), hyperperspiration (16%), drowsiness (5%), urinary wavering or urinary retention (4%), hypotension (7%), and sinusal tachycardia (6%)	

Rampello 2004	reboxetine: dry mouth (22%), constipation (18%), hyperperspiration (16%), insomnia (4%),drowsiness (3%), urinary wavering or urinary retention (4%), hypotension (8%), and sinusal tachycardia (7%).	placebo: dry mouth (19%), constipation (15%), hyperperspiration (12%), insomnia (5%),drowsiness (5%), hypotension (2%), and sinusal tachycardia (1%).	
Huang 2005	fluoxetine:8 patients(27%) had adverse events, and 2 of them might be linked to the medication (Nausea, thirsty)	clomipramine:13 patients (43%) had adverse events, 10 of them might be linked to the medication (thirsty, constipation, voiding dysfunction, dizziness and excitation)	
Ye 2006	paroxetine: unfollowed 1; Nausea 2;	imipramine: refused treatment 3 (because of xerostomia, constipation, blurred vison, cardiovascular side effects)	control: death 1(ICH);unfollowed 2
Li 2008	TCM:2 Nausea;	fluoxetine: Nausea 6;insomnia 4; second stroke 2	placebo:3 Nausea; 2 insomnia; 2 aggravated symptoms of depression
Cravello 2009	fluoxetine: insomnia; Nausea, fatigability, cephalalgia, and dizziness(all events were mild)	venlafaxine: headache, insomnia, dry mouth, agitation, sweating, and urinary retention; blood pressure increase(all events were mild)	
Dimitrios 2012	duloxetine: Nausea 3(15%); somnolence 3(15%); insomnia 1(5%); dizziness 2(10%); dry mouth 2(10%); headache 2(10%)	citalopram: Nausea 4(20%); somnolence 4(20%);dry mouth 2(10%); diarrhea 2(10%);	sertraline: Nausea 5(25%); somnolence 3(15%); insomnia 4(20%); dry mouth 3(15%); diarrhea 4(20%)

Jorge 2004	All adverse events registered during the course of the study were categorized as mild. Transient headaches 6, local discomfort 5, exacerbation of initial insomnia 1. There were no significant differences in the frequency of adverse events between the active and the sham rTMS groups.							
Jorge 2008	active-12k: local pain 1(7%); headache 5(33%); local discomfort 4(27%); anxiety 2(13%); active-18k:local pain 1(3%); headache 7(21%); local discomfort 3(9%);							
Narushima 2010	NR							
Tenev 2010	NR							
Seo 2016	No adverse side effects were reported							
Feng 2004		NR						
Williams 2007	intervention: death 2(ICH); seizure 2; 15 (16%) of intervention group subjects had antidepressant side effects bothersome enough to change medications, and 4 subjects changed medications more than once. The most common of the 39 side effects reported by these 15 subjects was sedation (14), followed by sexual (7), gastrointestinal (6), and anxiety (4) side effects	control: death 1 (myocardial infarction); seizure 1						
Mitchell 2009	NR							

rTMS= Repetitive Transcranial Magnetic Stimulation


TCM= traditional Chinese medicine

Appendix 5: Risk of bias assessments within studies


We used an updated "Risk of bias" tool from the Cochrane Collaboration recommends. This tool addresses seven specific bias domains including methods for generating the random sequence, allocation concealment, blinding of participants and investigators, blinding of outcome assessment, incompleteness of outcome data and selective outcome reporting. Each item is adjudicated within each study and the results are represented in a risk of bias table. We considered allocation concealment adequate if the investigators responsible for patient selection were unable to suspect before allocation which treatment was next. We considered blinding of patients adequate if interventions were described as indistinguishable, or if double-dummy technique was used. We considered blinding of therapists adequate if it was explicitly mentioned in the text that therapists were blinded. We considered incomplete outcome data if it excluded at least one of the randomly assigned patients from the analysis.

Publication bias and selective might affect interventions and comparisons in different ways depending on the clinical context in the network meta-analysis. Using methodology from ecology, attempts have been made to associate the possibility of selection bias with asymmetry measures of the network. Funnel plot asymmetry can be caused by the association between sample size, heterogeneity, and the probability of publication. Sponsorships bias may reflect subtle or less subtle differences in the study designs or the conduct of a trial that only supports the preferred strategy.

(A) Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.




(B)Study-level risk of bias




Small-study effects assessed via comparison -adjusted network funnel plots. In this presentation, all studies are centered on the summary effect estimate of their respective comparisons [μ XY (logOR for present study)] which is represented by the vertical red line. Individual study-level effect size is represented by yiXY [where X and Y are two study agents]. The green line represents linear regression of the comparison specific differences yi - μ XY on the standard error of yi. Outer dotted lines indicate the triangular region within which 95% of studies are expected to lie in the absence of both biases and heterogeneity (logOR ± 1.96*standard error). Please note that this is drawn only for comparisons with 2 or more studies.

(C) Publication bias assessed via funnel plots assessed for reduction of HAMD score between individual treatment




SSRI= selective serotonin reuptake inhibitor. TCA= tricyclic antidepressant. SNRI= serotonin-norepinephrine reuptake inhibitors. NRI= norepinephrine reuptake inhibitor. TCM= traditional Chinese medicine. rTMS= Repetitive Transcranial Magnetic Stimulation. P+A= psychotherapy plus antidepressants. N+A= nimodipine plus antidepressants.

(D) Publication bias assessed via funnel plots assessed for reduction of HAMD score between individual pharmacotherapy




FEWP=Free and Easy Wanderer Plus (a kind of Chinese medicine; its original Chinese Name is Jia-Wei-Xiao-Yao-San)

(E) Publication bias assessed via funnel plots assessed for response rate between individual treatment



SSRI= selective serotonin reuptake inhibitor. TCA= tricyclic antidepressant. TCM= traditional Chinese medicine. rTMS= Repetitive Transcranial Magnetic Stimulation. P+A= psychotherapy plus antidepressants. N+A= nimodipine plus antidepressants.

(F) Publication bias assessed via funnel plots assessed for remission rate between individual treatment



SSRI= selective serotonin reuptake inhibitor. TCA= tricyclic antidepressant. rTMS= Repetitive Transcranial Magnetic Stimulation. P+A= psychotherapy plus antidepressants. N+A= nimodipine plus antidepressants.

Table1. Risk of bias and sponsorship of included studies

Study	Random sequence generation	Allocation concealment	Participant blinding	Investigator binding	Incomplete outcome data	Selective reporting	Other source of bias	Industry sponsorship
-------	----------------------------	---------------------------	----------------------	----------------------	-------------------------	---------------------	----------------------	----------------------

			i.		i.			
Lipsey 1984	Low	Low	Low	Low	Low	Low	Low	Low
Andersen 1994	Low	Low	Low	Low	low	Low	Low	Low
Gonzalez 1995	High ^a	Unclear	Unclear	Unclear	Low	Low	Low	Unclear
Robinson 2000	Unclear	Unclear	Low	Low	High ^b	Low	Low	Unclear
Kimura 2000	Unclear	Unclear	Low	Low	Low	Low	Unclear	Low
Taragano 2001	Low	Low	Low	Low	Low	Low	Unclear	Low
Fruehwald 2003	Low	Low	Low	Low	Low	Low	Low	Unclear
Kimura 2003	Unclear	Unclear	Low	Low	Unclear	Low	Unclear	Low
Rampello 2003	Low	Low	Low	Low	Low	Low	Low	Unclear
Rampello 2004	Low	Low	Low	Low	Low	Low	Low	Unclear

1		1		1		i ali	1	
Huang 2005	Unclear	Unclear	Unclear	Unclear	Low	Low	Low	Unclear
Ye 2006	Unclear	Unclear	Low	Low	Low	Unclear	Low	Unclear
Li 2008	Low	Low	Low	Low	Low	Low	Low	Low
Cravello 2009	Unclear	Unclear	High	Low	Low	Unclear	Low	Unclear
Dimitrios 2012	Unclear	Unclear	High	High	Low	Low	Low	Low
Jorge 2004	Unclear	Unclear	Low	Low	Low	Low	Low	Low
Jorge 2008	Unclear	Unclear	Low	Low	Low	Low	Low	Low
Narushima 2010	Unclear	Unclear	Unclear	Unclear	Unlclear	Unclear	Low	Low
Tenev 2010	Unclear	Unclear	Low	Low	Low	Low	Low	Unclear
Seo 2016	Unclear	Unclear	Low	Low	Low	Low	Low	Low

Feng 2004	Unclear	Unclear	Unclear	Unclear	Low	Low	Low	Unclear
Williams 2007	Low	Low	High	Low	Low	Low	Unclear ^c	Low
Mitchell 2009	Low	Low	Unclear	Low	Low	Low	Low	Low


^a the intervention group and control group were divided randomly, but the 2 intervention group were divided according to their medical condition.

^b the dropout rate was significantly greater in the fluoxetine group than in the nortriptyline and placebo groups (χ 2=4.10, df=1, p=0.04)

^c52 of the 93 control subjects (56%) took an antidepressant at some time during the 12-week study period

Appendix 6: Network plot for each outcome


(A) Network diagram of eligible comparisons for response rate between individual treatment



A=control; B=TCA; C=N+A; D=TCM; E=SSRI; F=rTMS; G=P+A

- SSRI= selective serotonin reuptake inhibitor
- TCA= tricyclic antidepressant
- N+A= nimodipine plus antidepressants
- TCM= traditional Chinese medicine
- rTMS= Repetitive Transcranial Magnetic Stimulation
- P+A= psychotherapy plus antidepressants

(B) Network diagram of eligible comparisons for remission rate between individual treatment



A=control; B=TCA; C=N+A; D=SSRI; E=rTMS; F=P+A

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

N+A= nimodipine plus antidepressants

rTMS= Repetitive Transcranial Magnetic Stimulation

P+A= psychotherapy plus antidepressants

Appendix 7: Assessment of inconsistency

1. Evaluation of the local inconsistency by loop specific approach


(A) Evaluation of the local inconsistency for HAMD score change

			95%CI	Loop-specific
Loop		IF	(truncated)	Heterogeneity(τ^2)
Control-NRI-SSRI		6.07	(0.00,12.60)	2.488
Control-P+A-SSRI	-	2.01	(0.00,5.23)	0.984
Control-SSRI-TCA	-	0.69	(0.00,3.09)	0.965

(B) Evaluation of the local inconsistency for patient response rate

		95%CI	Loop-specific
	IF	(truncated)	Heterogeneity(τ^2)
•	0.24	(0.00,1.98)	0.288
			IF (truncated)

(C) Evaluation of the local inconsistency for patient remission rate



2. Evaluation of the inconsistency by node-splitting model Tests

(A) Evaluation of the inconsistency by node-splitting model tests for HAMD score change

Name	Direct Effect	Indirect Effect	P-Value
NRI vs. Control	-13.35 (-26.28, -0.22)	-4.76 (-15.01, 5.67)	0.29
NRI vs. SSRIs	0.66 (-8.72, 9.68)	-8.10 (-21.98, 5.79)	0.27

Control vs. P+A	1.98 (-10.90, 14.66)	13.17 (-0.78, 26.73)	0.23
Control vs. SSRIs	6.26 (0.59, 11.99)	7.66 (-1.89, 16.97)	0.79
Control vs. TCA	8.30 (2.82, 13.88)	4.88 (-9.63, 19.84)	0.64
P+A vs. SSRIs	-6.18 (-18.77, 7.04)	4.96 (-8.71, 18.77)	0.23
SSRIs vs. TCA	1.38 (-5.68, 8.48)	-0.71 (-10.67, 9.22)	0.72

(B) Evaluation of the inconsistency by node-splitting model tests for patient response rate

Name	Direct Effect	Indirect Effect	P-Value
Control vs. TCA	2.01 (0.80, 3.30)	0.77 (-1.96, 3.43)	0.35
Control vs. SSRI	0.82 (-0.45, 1.93)	2.04 (-0.75, 4.74)	0.35
TCA vs. SSRI	-0.86 (-2.40, 0.56)	-0.95 (-3.14, 1.16)	0.93

(C) Evaluation of the inconsistency by node-splitting model tests for patient remission rate

Name	Direct Effect	Indirect Effect	P-Value
Control vs. SSRI	1.43 (-0.25, 3.37)	-0.50 (-3.43, 2.56)	0.16
Control vs. P+A	0.77 (-1.32, 2.80)	2.85 (0.29, 5.72)	0.14
SSRI vs. P+A	1.38 (-0.64, 3.36)	-0.60 (-3.33, 1.90)	0.14

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

P+A= psychotherapy plus antidepressants

Appendix 8: Treatment ranking and SUCRA plot for each outcome

(A) All treatment

Treatment strategy	HAMD overall change	Patient response rate	Patient remission rate
N+A	0.9487	0.5431	0.6937
NRI	0.6906	-	-
ТСА	0.5568	0.8056	0.6733
P+A	0.5242	0.3413	0.3402
SSRI	0.5205	0.4014	0.3841
ТСМ	0.4592	0.4954	-
SNRI	0.3832	-	-
Psychotherapy	0.3237	-	-
rTMS	0.3041	0.8648	0.8389
Control	0.2910	0.0484	0.0699

Larger SUCRAs denote better procedure.

(B) Pharmacotherapy

Treatment strategy	HAMD overall change	Patient response rate	Patient remission rate
Paroxetine	0.9087	0.7113	0.5221
Imipramine	0.6996	0.6756	0.4728
Reboxetione	0.6868	-	-
Nortriptyline	0.6342	0.8322	-

Duloxetine	0.6105	-	-
Citalopram	0.5992	-	0.9844
Sertraline	0.4332	-	-
Psychotherapy	0.4137	-	-
FEWP	0.4101	0.4659	-
Fluoxetine	0.3280	0.3043	-
Clomipramine	0.3272	0.3221	-
Venlafaxine	0.2421	-	-
Control	0.1511	0.1889	0.0232

Larger SUCRAs denote better procedure.

SSRI= selective serotonin reuptake inhibitor

TCA= tricyclic antidepressant

SNRI= serotonin-norepinephrine reuptake inhibitors

NRI= norepinephrine reuptake inhibitor

N+A= nimodipine plus antidepressants

TCM= traditional Chinese medicine


rTMS= Repetitive Transcranial Magnetic Stimulation

P+A= psychotherapy plus antidepressants

FEWP=Free and Easy Wanderer Plus (a kind of Chinese medicine; its original Chinese Name is Jia-Wei-Xiao-Yao-San)


Appendix 9: Subgroup analysis

(A) Network diagram of eligible comparisons for response rate between individual pharmacotherapy



A= control; B=paroxetine; C=imipramine; D=clomipramine; E=nortriptyline; F= Free and Easy Wanderer Plus(a kind of Chinese medicine; its original Chinese Name is Jia-Wei-Xiao-Yao-San); G=fluoxetine

(B) Network diagram of eligible comparisons for remission rate between individual pharmacotherapy



A= control; B=paroxetine; C=imipramine; D=citalopram

Nortriptyline						
1.55 (0.06 - 45.38)	Paroxetine					
1.73 (0.06 - 46.36)	1.16 (0.07 - 18.58)	Imipramine				
4. 30 (0. 22 - 73. 15)	2.99 (0.06 - 100.49)	2.48 (0.05 - 96.71)	FEWP			
7.68 (0.25 - 269.20)	5.00 (0.07 - 444.64)	4. 41 (0. 07 - 348. 19)	1.74 (0.05 - 88.86)	Clomipramine		
7.18 (1.14 - 68.40)	4.95 (0.20 - 131.23)	4.04 (0.18 - 109.08)	1.59 (0.18 - 20.07)	0.94 (0.06 - 17.69)	Fluoxetine	
10. 02 (1. 82 - 52. 56)	6.66 (0.36 - 99.90)	5.73 (0.32 - 86.56)	2.32 (0.21 - 26.02)	1.30 (0.04 - 28.24)	1. 43 (0. 26 - 5. 56)	Control

figure A: Summary odds ratio (OR) and credible intervals from network meta-analysis of response rate of individual pharmacotherapy

Treatments are reported in order of efficacy ranking according to SUCRAs. Comparisons should be read from left to right. The response rate and remission rate estimate is located at the intersection of the column-defining treatment and the row-defining treatment. An OR value below 1 favours the column-defining treatment. To obtain ORs for comparisons in the opposing direction, reciprocals should be taken. Significant results are in bold and underlined. FEWP=Free and Easy Wanderer Plus (a kind of Chinese medicine; its original Chinese name is Jia-Wei-Xiao-San)

Citalopram			
3. 97 (1. 29 - 12. 04)	Paroxetine		
4.55 (0.82 - 26.81)	1. 14 (0. 34 - 4. 25)	Imipramine	
18. 50 (2. 75 - 149. 70)	4. 57 (1. 00 - 28. 00)	4. 04 (0. 84 - 23. 78)	Control

figure B: Summary odds ratio (OR) and credible intervals from network meta-analysis of remission rate of individual pharmacotherapy

Treatments are reported in order of efficacy ranking according to SUCRAs. Comparisons should be read from left to right. The response rate and remission rate estimate is located at the intersection of the column-defining treatment and the row-defining treatment. An OR value below 1 favours the column-defining treatment. To obtain ORs for comparisons in the opposing direction, reciprocals should be taken. Significant results are in bold and underlined. FEWP=Free and Easy Wanderer Plus (a kind of Chinese medicine; its original Chinese name is Jia-Wei-Xiao-Yao-San)

Appendix 10: Post hoc analysis

Study	Location	Participants	Intervention/control (N)	Drop-out rate	Treatment	Follow-up	Setting	Center	Depression	Population
		(N)		(%)	duration				Diagnostic criteria	
Wiart 2000	France	31	Fluoxetine 16	12.5	45 days	45days	inpatient	single center	ICD-10	ITT
			Placebo	0						
Murray 2005	Sweden	123	Sertraline 62	18	6 weeks	26 weeks	inpatient	multi-center	DSM-IV	ITT
			Placebo 61	10						

Study	intervention/control	Mean age	Gender	Mean baseline	Hemisphere stroke side	Depression diagnosis	Time since stroke onset
	(N)	(SD)	(%, male)	HAMD/MADRS (SD)	(%, left)	N (%, major depression)	
Wiart 2000	Fluoxetine(N=16)	66.3(7.1)	56.3	28.5(7.7)	25	100%	47.1(21.6) days
	Placebo(N=15)	68.9(11.6)	40	27.2(6.3)	20		47.7(19.9) days
Murray 2005	Sertraline(N=62)	70.7(9.7)	51.6	18.9(6.1)	56.6	66.1	137.3(101.4) days
	Place(N=61)	70.7(10.1)	44.3	19.6(6.1)	33.3	57.4	119.0(92.5) days

Results of Post hoc sensitivity analysis

Post hoc sensitivity analysis of primary main outcome							
		Rankings of post	Rankings of				
		hoc sensitivity	previous				
Comparisons	Network Meta-Analysis	analysis	analysis				
N+A VS CONTROL	9. 29 (-0. 28, 18. 42)	1	1				
NRI VS CONTROL	8.44(2.67,14.26)	2	2				
TCA VS CONTROL	7.72(4.13,11.29)	3	3				

P+A VS CONTROL	7. 41 (0. 81, 14. 38)	4	4				
SSRI VS CONTROL	6. 60 (3. 43, 9. 79)	5	5				
SNRI VS CONTROL	6. 22 (-2. 00, 13. 70)	<u>6</u>	<u>7</u>				
TCM VS CONTROL	5. 71 (-2. 26, 13. 33)	<u>7</u>	<u>6</u>				
Psychotherapy VS CONTROL	4.88(-4.45,14.40)	8	8				
rTMS VS CONTROL	3. 57 (-0. 77, 7. 81)	9	9				
Post hoc sensitivity analysis of subgroup analysis							
		Rankings of post	Rankings of				
		hoc sensitivity	previous				
Comparisons	Network Meta-Analysis	analysis	analysis				
Paroxetine VS Placebo	<u>13. 26 (3. 32, 23. 11)</u>	1	1				
Imipramine VS Placebo	<u>11. 30 (1. 43, 21. 58)</u>	2	2				
Reboxetine VS Placebo	<u>8. 52 (1. 53, 15. 24)</u>	3	3				
Nortriptyline VS Placebo	<u>7.75(3.77,12.07)</u>	4	4				
Citalopram VS Placebo	<u>6.63(0.29,12.64)</u>	<u>5</u>	<u>6</u>				
Duloxetine VS Placebo	5.72(-4.64,16.37)	<u>6</u>	<u>6</u> <u>5</u> 9				
Fluoxetine VS Placebo	5.15(0.40,9.72)	<u>7</u>	<u>9</u>				
FEWP VS Placebo	4.98(-3.21,13.35)	8	8				
Venlafaxine VS Placebo	3. 47 (-7. 20, 14. 20)	<u>9</u>	<u>11</u>				
Clomipramine VS Placebo	3. 86 (-5. 96, 14. 43)	10	10				
Sertraline VS Placebo	3. 02 (-4. 96, 11. 03)	<u>11</u>	<u>7</u>				